Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 151 to 160 of 2422

TitleReference numberPublishedLast updated
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Velmanase alfa for treating alpha-mannosidosisHST29
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Acne vulgaris: managementNG198
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismIPG778
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932

Results per page

  1. 10
  2. 25
  3. 50
  4. All